Abstract Library

#4417 Efficacy of immune checkpoint inhibitors (ICI) in patients with advanced pancreatic NETs displaying high TMB and MMR alterations following treatment with alkylating agents

Introduction: Alkylating chemotherapy (ALK) is frequently used in patients with PanNETs. It may favour grade progression and acquisition of a hypermutator phenotype associated with frequent alterations of the MMR genes, suggesting a potential benefit of ICI.

Conference:

Presenting Author:

Authors: de Mestier L, Apostolidis L, Koumarianou A, Hernando Cubero J, Riechelmann R,

Keywords: immune checkpoint inhibitor, immunotherapy, hypermutagenicity, alkylating agents, tumour mutational burden, mismatch repair,

#4388 Pancreatic neuroendocrine tumours (pNET) and MUTYH germline (GPV) and somatic (SPV) pathogenic variants: A multinational study

Introduction: GPV and SPV in MUTYH are rare in pNET patients (pts).

Conference:

Presenting Author: Riechelmann R

Authors: Riechelmann R, Torrezan G, Cingarlini S, Raj N, Bergsland E,

Keywords: pancreatic neuroendocrine tumour, MUTYH, germline, pathogenic variants, mutations,

#4330 Clinical and gut microbiota (GM) markers of aggressive carcinoid syndrome (CS)

Introduction: While most patients (pts) with CS present indolent disease (iCS), others have aggressive disease (aCS). Little is known about biomarkers of aCS.

Conference:

Presenting Author: Riechelmann R

Authors: Riechelmann R, Henrique K, Durant L, Iebba V, Derosa L,

Keywords: neuroendocrine tumour, carcinoid syndrome, gut microbiome,

#4306 EVENET: Randomised phase II trial of everolimus 5mg vs. 10mg daily in patients with neuroendocrine tumours

Introduction: Everolimus 10mg PO daily is approved for patients (pts) with advanced G1/G2 neuroendocrine tumours (NET) but is associated with significant toxicity, including 20% of serious infections in real-world pts. In phase I trials, 5mg/day was sufficient to inhibit the mTOR pathway. Retrospective data suggest that 5mg/day is similarly effective to 10mg/day but less toxic.

Conference:

Presenting Author:

Authors: Riechelmann R, Campos A, Durant L, Bulzico D,

Keywords: everolimus, neuroendocrine tumour, dose optimisation, toxicity,

#4305 Lower dose of lenvatinib is similarly effective as higher dose for patients (pts) with advanced neuroendocrine tumours (NETs): A multinational retrospective cohort

Introduction: A phase II trial with lenvatinib 24mg PO daily was effective for pts with gastroenteropancreatic (GEP) NETs but led to significant toxicity. In clinical practice, dose reductions are commonly required.

Conference:

Presenting Author: Riechelmann R

Authors: Zanetta G, Grozinsky-Glasberg S, Bel-Ange A, Barros M, Felismino T,

Keywords: lenvatinib, neuroendocrine tumour, dose optimisation, toxicity,